Prediction Model for Gastric Cancer With DNA Mismatch Repair Deficiency.
Adult
Aged
Aged, 80 and over
Area Under Curve
Biomarkers, Tumor
/ metabolism
DNA Mismatch Repair
DNA-Binding Proteins
/ deficiency
Female
Humans
Male
Middle Aged
Mismatch Repair Endonuclease PMS2
/ deficiency
MutL Protein Homolog 1
/ deficiency
Neoplasm Grading
Neoplasm Invasiveness
Sex Characteristics
Stomach Neoplasms
/ metabolism
Tumor Burden
Young Adult
Defective mismatch repair
anti-PD-1 blockade
gastric cancer
microsatellite instability
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
10
12
2020
revised:
22
12
2020
accepted:
11
01
2021
entrez:
31
1
2021
pubmed:
1
2
2021
medline:
7
2
2021
Statut:
ppublish
Résumé
DNA mismatch repair (MMR) deficiency has received increasing attention as a biomarker of anti-PD-1 treatments of solid tumors including gastric cancer (GC). However, efficient screening has not been established. A total of 513 patients were tested for the expression of MMR proteins by immunohistochemistry to identify MMR deficient GC. Development of a prediction model was attempted using the common clinicopathological features. In total, 11% (57/513) of the patients showed loss of expression of either one or more MMR proteins (MMR protein deficiency; MMR-D). Multivariate analysis demonstrated that age (≥70 years), sex (female), tumor location (lower 1/3), depth invasion (low, T1/T2/T3), and absence of distant metastasis were significantly independent predictive factors of MMR-D GCs. The MMR-D GC probability estimated by the prediction model ranged from 0.4% to 62.2%, and the area under the curve of the receiver operating characteristics curve was 0.82 (95% confidence interval=0.75-0.87). Our prediction model can sufficiently and efficiently identify MMR-D GCs using clinical features.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
DNA mismatch repair (MMR) deficiency has received increasing attention as a biomarker of anti-PD-1 treatments of solid tumors including gastric cancer (GC). However, efficient screening has not been established.
PATIENTS AND METHODS
METHODS
A total of 513 patients were tested for the expression of MMR proteins by immunohistochemistry to identify MMR deficient GC. Development of a prediction model was attempted using the common clinicopathological features.
RESULTS
RESULTS
In total, 11% (57/513) of the patients showed loss of expression of either one or more MMR proteins (MMR protein deficiency; MMR-D). Multivariate analysis demonstrated that age (≥70 years), sex (female), tumor location (lower 1/3), depth invasion (low, T1/T2/T3), and absence of distant metastasis were significantly independent predictive factors of MMR-D GCs. The MMR-D GC probability estimated by the prediction model ranged from 0.4% to 62.2%, and the area under the curve of the receiver operating characteristics curve was 0.82 (95% confidence interval=0.75-0.87).
CONCLUSION
CONCLUSIONS
Our prediction model can sufficiently and efficiently identify MMR-D GCs using clinical features.
Identifiants
pubmed: 33517304
pii: 41/2/975
doi: 10.21873/anticanres.14851
doi:
Substances chimiques
Biomarkers, Tumor
0
DNA-Binding Proteins
0
G-T mismatch-binding protein
0
MLH1 protein, human
0
PMS2 protein, human
EC 3.6.1.-
Mismatch Repair Endonuclease PMS2
EC 3.6.1.3
MutL Protein Homolog 1
EC 3.6.1.3
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
975-982Informations de copyright
Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.